Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of intravesical GemRIS in muscle-invasive bladder cancer before cystectomy
NL-OMON46772Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gemcitabine-releasing intravesical system in bladder cancer and muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Safety of GemRIS upon insertion, two 7-day exposures and removals. Started Aug 2018; status: completed.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON46772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46772.